Treatment of stage II chronic arterial disease of the lower limbs with the serotonergic antagonist naftidrofuryl: results after 6 months of a controlled, multicenter study

• Published in: Journal of cardiovascular pharmacology Vol. 16 Suppl 3; p. S75
• Main Authors: Adhoute, G, Andreassian, B, Boccalon, H, Cloarec, M, Di Maria, G, Lefebvre, O, Mondine, P, Plagnol, P, Pointel, J P, Quancard, X
• Format: Journal Article
• Language: English
• Published: United States 1990
• Subjects: Adult; Aged; Arteriosclerosis - complications; Arteriosclerosis - drug therapy; Chronic Disease; Double-Blind Method; Female; Follow-Up Studies; Humans; Intermittent Claudication - drug therapy; Intermittent Claudication - etiology; Male; Middle Aged; Nafronyl - therapeutic use; Serotonin Antagonists - therapeutic use; Single-Blind Method
• ISSN: 0160-2446; 1533-4023
• DOI: 10.1097/00005344-199000163-00018

A study was carried out in patients with intermittent claudication (Fontaine's stage II). The atheromatous origin of the disease was confirmed and localized by angiography or Doppler. One hundred eight-three patients were selected initially (day -30) with a pain-free walking distance on a treadmill (at a speed of 3 km/h and a slope of 10%) ranging from 150 to 300 m. During the first month (washout period) all patients received two placebo tablets daily. At the end of this run-in period (day -30; day 0) and after checking walking distance stability (allowed variation: 20% between the two measurements), patients were included in the study. According to this criterion, 112 patients were selected and 94 remained during the whole study. The study was designed in double-blind, using two parallel, randomly selected groups. Fifty-two patients received naftidrofuryl (2 x 316.5 mg tablets daily with meals) for 6 months; 42 patients received placebo under the same conditions. During this period, clinical and paraclinical examinations were carried out every quarter (day 90 and day 180). After checking the initial homogeneity of the naftidrofuryl and placebo groups, the comparison between the two groups indicates a significant improvement in the naftidrofuryl group after 3 months and 6 months of treatment, for the pain-free walking distance. For the maximal walking distance, a significant improvement was found at day 180. Nonparametric analysis (chi 2 test) also indicated a significant improvement for the naftidrofuryl group. These results confirm that naftidrofuryl is beneficial in the treatment of patients with chronic arterial disease.